These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 38225440

  • 1. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    He WJ, Wang J, Liu N, Li GY, Zhu XW, Yao L, Liu LL.
    J Nephrol; 2024 May; 37(4):933-940. PubMed ID: 38225440
    [Abstract] [Full Text] [Related]

  • 2. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 3. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
    Chen S, Yin Q, Ren S, Zhong X, Wang W, Li G, Wang L.
    Sci Rep; 2018 Sep 12; 8(1):13662. PubMed ID: 30209279
    [Abstract] [Full Text] [Related]

  • 5. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb 12; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppressive agents for treating IgA nephropathy.
    Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Mar 12; 3(3):CD003965. PubMed ID: 32162319
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
    Ni Z, Zhang Z, Yu Z, Lu F, Mei C, Ding X, Yuan W, Zhang W, Jiang G, Sun M, He L, Deng Y, Pang H, Qian J.
    Ren Fail; 2021 Dec 12; 43(1):1214-1221. PubMed ID: 34396911
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Hydroxychloroquine in Patients with IgA Nephropathy: A Meta-Analysis.
    Zhang Z, Liu X, Ye P, Xie C, Kong Y.
    Arch Esp Urol; 2024 Jan 12; 77(1):16-24. PubMed ID: 38374008
    [Abstract] [Full Text] [Related]

  • 10. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar 12; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 11. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    BMC Nephrol; 2017 Mar 14; 18(1):89. PubMed ID: 28292274
    [Abstract] [Full Text] [Related]

  • 12. Hydroxychloroquine in IgA nephropathy: a systematic review.
    Stefan G, Mircescu G.
    Ren Fail; 2021 Dec 14; 43(1):1520-1527. PubMed ID: 34779707
    [Abstract] [Full Text] [Related]

  • 13. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
    Yu MY, Kim YC, Koo HS, Chin HJ.
    PLoS One; 2017 Dec 14; 12(11):e0188375. PubMed ID: 29155873
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.
    Li Y, Xiong Y, Huang T, Liu X, Xu G.
    BMC Nephrol; 2021 Nov 04; 22(1):364. PubMed ID: 34736419
    [Abstract] [Full Text] [Related]

  • 15. Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy.
    Yang YZ, Liu LJ, Shi SF, Wang JW, Chen YQ, Lv JC, Zhang H.
    Am J Nephrol; 2018 Nov 04; 47(3):145-152. PubMed ID: 29502121
    [Abstract] [Full Text] [Related]

  • 16. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
    Min L, Wang Q, Cao L, Zhou W, Yuan J, Zhang M, Che X, Mou S, Fang W, Gu L, Zhu M, Wang L, Yu Z, Qian J, Ni Z.
    Oncotarget; 2017 Jul 18; 8(29):48375-48384. PubMed ID: 28415636
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.
    Tang C, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H.
    J Nephrol; 2022 Mar 18; 35(2):429-440. PubMed ID: 33591553
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy
.
    Ihm HS, Lee JY, Hwang HS, Kim YG, Moon JY, Lee SH, Jeong KH, Lee TW, Ihm CG.
    Clin Nephrol; 2019 Sep 18; 92(3):131-140. PubMed ID: 31232271
    [Abstract] [Full Text] [Related]

  • 19. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
    Gao R, Wu W, Wen Y, Li X.
    Int Urol Nephrol; 2017 Jul 18; 49(7):1233-1241. PubMed ID: 28349446
    [Abstract] [Full Text] [Related]

  • 20. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, Hirakata H, Kitazono T, Tsuruya K.
    Clin Exp Nephrol; 2016 Oct 18; 20(5):689-698. PubMed ID: 26564155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.